At the JPM conference, Pfizer CEO Albert Bourla projected optimism, saying the market was overlooking the pharma company's ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.

Sasanlimab (PF-06801591) added to BCG therapy significantly improved outcomes for patients with BCG-naive, high-risk ...

Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain ...

The trial showed a 'clinically meaningful' and 'statistically significant' improvement when treated with therapy plus BCG, ...

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Pfizer’s sasanlimab in combo with BCG improves EFS in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Monday, January 13, 2025, 13:00 Hrs [IST] ...

Pfizer is expected to rebound in 2025 with growth stabilized and dividend growth to continue. Learn why PFE stock is a Buy.

Patients in the study with advanced bladder cancer had less risk of cancer progressing or returning when treated with ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational ...

Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...